secwatch.observer — SEC 8-K summary
======================================

Issuer:     PepGen Inc. (PEPG)
CIK:        0001835597
Form:       8-K
Filed at:   2026-05-12T20:10:18+00:00
Accession:  0001193125-26-219424
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PepGen Q1 net loss $17.8M; cash $132.3M; 10 mg/kg DM1 cohort fully enrolled
---------------------------------------------------------------------------

- Net loss of $17.8M ($0.26 per share) vs $30.2M loss in Q1 2025; R&D spend down to $13.0M from $25.4M.
- Cash, equivalents and marketable securities $132.3M; funding seen into 2H 2027.
- FREEDOM2-DM1 5 mg/kg cohort showed favorable safety, splicing and vHOT trends; 10 mg/kg cohort fully enrolled with data expected 2H 2026.
- FDA partial clinical hold on FREEDOM2 relates to preclinical studies; timing of ongoing trial not impacted.
- 13 patients enrolled in open-label extension at 5 mg/kg with no discontinuations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1835597/000119312526219424/0001193125-26-219424-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1835597/000119312526219424/pepg-20260512.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-219424

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer